Page last updated: 2024-08-02 14:45:50

a 443654

Description

A 443654: an Akt kinase inhibitor; structure in first source [MeSH]

(2S)-1-(1H-indol-3-yl)-3-[[5-(3-methyl-2H-indazol-5-yl)-3-pyridinyl]oxy]-2-propanamine : no description available [CHeBI]

Cross-References

ID SourceID
PubMed CID10172943
CHEMBL ID379300
SCHEMBL ID570604
CHEBI ID91351
MeSH IDM0489728

Synonyms (37)

Synonym
HY-10425
(2s)-1-(1h-indol-3-yl)-3-{[5-(3-methyl-1h-indazol-5-yl)pyridin-3-yl]oxy}propan-2-amine
L20 ,
bdbm15131
indazole-pyridine, 4
5-{5-[(2s)-2-amino-3-(1h-indol-3-yl)propoxy]pyridin-3-yl}-3-methyl-1h-indazole
a-443654
5-indazolyl pyridine 3
a 443654
(s)-1-(5-(3-methyl-1h-indazol-5-yl)pyridin-3-yloxy)-3-(1h-indol-3-yl)propan-2-amine
smr001307829
MLS002232275
DB08073
a-4436554
CHEMBL379300
NCGC00347278-01
CS-0405
SCHEMBL570604
gtpl8204
(2s)-1-(1h-indol-3-yl)-3-[5-(3-methyl-2h-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine
552325-16-3
a443654
DTXSID20436347
AKOS030526845
CHEBI:91351
NCGC00347278-02
(s)-1-(1h-indol-3-yl)-3-[5-(3-methyl-2h-indazol-5-yl)pyridin-3-yl]oxypropan2-amine
EX-A7113
Q27074073
F83982
a-654
(2s)-1-(1h-indol-3-yl)-3-[[5-(3-methyl-1h-indazol-5-yl)-3-pyridyl]oxy]propan-2-amine
Z2037280935
1h-indole-3-ethanamine, alpha-[[[5-(3-methyl-1h-indazol-5-yl)-3-pyridinyl]oxy]methyl]-, (alphas)-
a-443644
Q4UG565ZYH
a 443644

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.

Protein Targets (29)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency35.4813AID504339
glp-1 receptor, partialHomo sapiens (human)Potency0.5012AID624417
Fumarate hydrataseHomo sapiens (human)Potency5.8992AID1347053
PPM1D proteinHomo sapiens (human)Potency2.6212AID1347411
TDP1 proteinHomo sapiens (human)Potency0.5805AID686978; AID686979
Smad3Homo sapiens (human)Potency1.3180AID588855; AID720534
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency0.9522AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency1.8401AID1259252; AID1259253; AID1259255; AID1259256
GVesicular stomatitis virusPotency0.6741AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency3.7908AID1645840
polyproteinZika virusPotency5.8992AID1347053
67.9K proteinVaccinia virusPotency1.0751AID720579; AID720580
IDH1Homo sapiens (human)Potency18.3564AID686970
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency2.5119AID504847
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency5.1735AID504444
flap endonuclease 1Homo sapiens (human)Potency44.6684AID588795
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.7943AID540303
plasminogen precursorMus musculus (house mouse)Potency0.7943AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.7943AID540303
gemininHomo sapiens (human)Potency1.4457AID624296; AID624297
Glycoprotein hormones alpha chainHomo sapiens (human)Potency2.5119AID624291
Interferon betaHomo sapiens (human)Potency2.1344AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.6741AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.6741AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.6741AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
cAMP-dependent protein kinase catalytic subunit alphaBos taurus (cattle)IC500.0165AID1797359; AID1797514
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)IC500.0007AID1797513; AID290872; AID436502; AID514326
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)Ki0.0002AID1797345; AID1876208; AID266586; AID514325
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)IC500.0152AID1797358; AID514328
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)IC500.0510AID514330

Bioassays (474)

Assay IDTitleYearJournalArticle
AID514816Inhibition of TBK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514015Inhibition of CLK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435873Percentage PLK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435230Percentage GSK3-beta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513806Inhibition of AURKB at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514809Inhibition of STK24 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435739Percentage p38-gamma activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514444Inhibition of MAPK14 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290875AUC in mouse at 10 mg/kg, po2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290892Selectivity for Akt1 over cKIT2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290886Selectivity for Akt1 over ERK22007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435584Percentage CaMK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513795Inhibition of ABL1 T315I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514426Inhibition of KIT at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435746Percentage PRAK activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514057Inhibition of FLT3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514483Inhibition of PKN1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514486Inhibition of PLK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435353Percentage HIPK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514785Inhibition of RET at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514331Inhibition of myristoylated AKT3 M229G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435366Percentage NEK2a activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514054Inhibition of FGFR4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514690Induction AKT1 Thr308 hyperphosphorylation in insulin-induced rat L6 cells at 10 uM after 20 mins before insulin stimulation by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514039Inhibition of EPHA4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435740Percentage PKCzeta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514786Inhibition of RET V804L mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514334Induction of AKT1 Ser473 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435379Percentage SmMLCK activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514467Inhibition of NTRK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514484Inhibition of PLK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514818Inhibition of TYRO3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514078Inhibition of JAK2 JH1 JH2 domain at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514777Inhibition of PRKD1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513794Inhibition of ABL1 G250E mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435243Percentage MARK3 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514461Inhibition of NEK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435543Percentage PKCzeta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514065Inhibition of GRK7 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514788Inhibition of ROCK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435538Percentage PDK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514012Inhibition of CDK5/p35 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514326Inhibition of myristoylated wild type AKT1 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514451Inhibition of MATK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514779Inhibition of PRKG1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435845Percentage CHK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435917Percentage PAK6 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435344Percentage DYRK1A activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514487Inhibition of PRKACA (PKA) at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435861Percentage JNK3 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513817Inhibition of CAMK2D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514037Inhibition of EPHA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514821Inhibition of PASK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290896Half life in mouse at 10 mg/kg, po2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID436502Inhibition of Akt2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
ISSN: 1768-3254
QSAR study of Akt/protein kinase B (PKB) inhibitors using support vector machine.
AID435733Percentage NEK6 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514042Inhibition of EPHB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513793Inhibition of ABL1 E255K mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435475Percentage MKK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435627Percentage ROCK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435730Percentage MAPKAPK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514440Inhibition of MAPK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514438Inhibition of MAP4K4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514488Inhibition of PRKCA at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514423Inhibition of JAK2 JH1 JH2 domain V617F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514446Inhibition of MAPKAPK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514047Inhibition of ERBB4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514469Inhibition of PAK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514781Inhibition of PRKX at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513810Inhibition of BRAF at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514056Inhibition of FLT1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514460Inhibition of NEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514480Inhibition of PHKG2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514472Inhibition of PAK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290888Selectivity for Akt1 over MAPK2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID513819Inhibition of CDC42 binding protein alpha at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID1876209Cytotoxicity against human HepG2 cells at 1 uM2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514052Inhibition of FGFR3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435371Percentage p38delta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435460Percentage CK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435927Percentage PKBalpha activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514433Inhibition of MAP2K2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435954Percentage AMPK activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514797Inhibition of RPS6KB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435594Percentage CK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514050Inhibition of FGFR1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435346Percentage EF2K activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514070Inhibition of HIPK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514791Inhibition of RPS6KA1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435108Percentage IKK-beta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514770Inhibition of PKCE at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514456Inhibition of MST1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514036Inhibition of EPHA1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514774Inhibition of PRKCN at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514434Inhibition of MAP2K6 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513786Induction of AKT1 Thr 308 phosphorylation in HEK293 cells at 2.5 uM after 15 mins by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513820Inhibition of CDC42 binding protein beta at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514430Inhibition of LYN A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435596Percentage CSK activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435736Percentage p38delta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514067Inhibition of GSK3B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513796Inhibition of ABL1 Y253F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514691Induction AKT1 Ser473 hyperphosphorylation in insulin-induced rat L6 cells at 10 uM after 20 mins before insulin stimulation by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514466Inhibition of NTRK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514798Inhibition of SGK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435467Percentage ERK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435919Percentage PIM1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435878Percentage PRK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435825Percentage PKCalpha activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435711Percentage CaMKKbeta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435853Percentage GSK3-beta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514455Inhibition of MINK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514071Inhibition of IGF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514010Inhibition of CDK1/cyclin B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290874Oral bioavailability in mouse at 10 mg/kg, po2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID513788Induction of AKT1 Thr 308 phosphorylation in HEK293 cells at 2.5 uM after 15 mins at 2.5 uM after 15 mins pretreated with pan-PI3K inhibitor PIK90 10 mins before compound addition by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514458Inhibition of MUSK at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514428Inhibition of LCK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435109Percentage JNK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514061Inhibition of FYN at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514449Inhibition of MARK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290882Selectivity for Akt1 over PKA2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290889Selectivity for Akt1 over CK22007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435882Percentage RSK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513782Induction of flag-tagged wild type AKT1 Thr308 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514450Inhibition of MARK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435128Percentage PKD1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435624Percentage PRK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513812Inhibition of BRSK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435611Percentage MARK3 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514780Inhibition of PRKG2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513807Inhibition of AURKC at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514792Inhibition of RPS6KA2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514035Inhibition of EGFR L861Q mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514046Inhibition of ERBB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514485Inhibition of PLK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514482Inhibition of PIM2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514024Inhibition of CSNK1G3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514453Inhibition of MET at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514796Inhibition of RPS6KA6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514806Inhibition of STK22B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290890Selectivity for Akt1 over KDR2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514424Inhibition of JAK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514772Inhibition of PRKCH at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435735Percentage NEK7 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435875Percentage PRAK activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513814Inhibition of CAMK1D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514778Inhibition of PRKD2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435247Percentage MNK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514793Inhibition of RPS6KA3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513816Inhibition of CAMK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514018Inhibition of CSK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435921Percentage PIM2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435598Percentage DYRK3 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435112Percentage MAPKAPK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514804Inhibition of SRPK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435362Percentage MELK activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID436063Percentage Aurora C activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513798Inhibition of ACVR1B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514060Inhibition of FRK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID436065Percentage BRSK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513802Inhibition of AKT2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435630Percentage RSK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513801Inhibition of AKT1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514814Inhibition of SYK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290891Selectivity for Akt1 over Flt12007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514468Inhibition of NTRK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514784Inhibition of RAF1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514072Inhibition of IKBKB at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514034Inhibition of EGFR L858R mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514470Inhibition of PAK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514813Inhibition of STK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435254Percentage p38beta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514051Inhibition of FGFR2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID266588Antiproliferative activity against human MiaPaCa2 cell line2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
ISSN: 0960-894X
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID435110Percentage Lck activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514819Inhibition of YES1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514028Inhibition of DCAMKL2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514073Inhibition of INSR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514795Inhibition of RPS6KA5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435583Percentage BRSK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514045Inhibition of EPHB4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514776Inhibition of PRKCZ at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435815Percentage PKBalpha activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435465Percentage ERK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID266586Inhibition of Akt1 in presence of 10 uM ATP2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
ISSN: 0960-894X
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID513811Inhibition of BRAF V599E mutant at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290893Selectivity for Akt1 over SRC2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514773Inhibition of PRKCI at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514044Inhibition of EPHB3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514425Inhibition of KDR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514068Inhibition of HCK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435381Percentage SRPK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435305Percentage PKA activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435470Percentage HIPK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514465Inhibition of NEK9 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435616Percentage NEK2a activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514069Inhibition of HIPK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435457Percentage CHK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID436035Percentage CaMKKbeta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514041Inhibition of EPHA8 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435354Percentage HIPK3 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513792Inhibition of ABL1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290897Toxicity assessed as decrease in MAP in dog infused at 0.48 mg/kg/min2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID290884Selectivity for Akt1 over PKCdelta2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514020Inhibition of CSNK1D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435813Percentage PIM3 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435249Percentage MSK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514032Inhibition of DYRK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID1876133Antiviral activity against HBV2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID514017Inhibition of CSF1R at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514478Inhibition of PDK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435224Percentage DYRK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514441Inhibition of MAPK11 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513803Inhibition of AKT3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514053Inhibition of FGFR3 K650E mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435849Percentage DYRK3 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435435Percentage CaMK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435127Percentage PAK4 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435990Percentage SGK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514327Inhibition of myristoylated AKT1 M227G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514442Inhibition of MAPK12 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435377Percentage S6K1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513805Inhibition of AMPK A1/B1/G1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435437Percentage PKBbeta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514049Inhibition of FES at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514058Inhibition of FLT3 D835Y mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435920Percentage PIM2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435178Percentage PKCalpha activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435975Percentage MKK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435337Percentage Aurora B activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435216Percentage Aurora B activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435817Percentage PKBbeta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514013Inhibition of CHEK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435610Percentage MAPKAPK3 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID429467Inhibition of AKT2 at 25 uM by FRET based assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
ISSN: 1464-3405
Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
AID429466Inhibition of AKT2 at 50 uM by FRET based assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
ISSN: 1464-3405
Discovery of a novel protein kinase B inhibitor by structure-based virtual screening.
AID435369Percentage p38alpha activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514040Inhibition of EPHA5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514471Inhibition of PAK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514474Inhibition of PDGFRalpha at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435617Percentage NEK6 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID290873Half life in mouse at 3 mg/kg, iv2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435752Percentage S6K1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514447Inhibition of MAPKAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513809Inhibition of BMX at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514439Inhibition of MAP4K5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514799Inhibition of SGK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290894Selectivity for Akt1 over Chk12007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514427Inhibition of KIT T670I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514055Inhibition of FGR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435359Percentage JNK3 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435498Percentage RSK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514064Inhibition of GRK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435122Percentage NEK7 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435715Percentage DYRK1A activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435239Percentage JNK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514812Inhibition of STK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435974Percentage MELK activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435870Percentage p38beta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514807Inhibition of STK22D at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513813Inhibition of BTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435132Percentage Src activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435609Percentage MAPKAPK3 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435187Percentage CDK2-cyclinA activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435732Percentage MSK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID290887Selectivity for Akt1 over GSK3-beta2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514325Inhibition of AKT12009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514043Inhibition of EPHB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514811Inhibition of STK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514059Inhibition of FLT4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514475Inhibition of PDGFRalpha D842V mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435217Percentage Aurora C activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514019Inhibition of CSNK1A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514048Inhibition of FER at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290899Toxicity assessed as prolongation of action potential duration in dog purkinje fibres at 20 uM2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435712Percentage CHK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514459Inhibition of MYLK2 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435916Percentage PAK6 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514808Inhibition of STK23 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514443Inhibition of MAPK13 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513815Inhibition of CAMK2A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513787Induction of membrane localization of AKT1 in HEK293 cells at 2.5 uM after 15 mins pretreated with pan-PI3K inhibitor PIK90 10 mins before compound addition by anti AKt antibody staining based fluorescence microscopy2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435846Percentage CSK activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435222Percentage CK1delta activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514022Inhibition of CSNK1G1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514038Inhibition of EPHA3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514775Inhibition of PRKCQ at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514782Inhibition of PTK2B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435111Percentage Lck activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435301Percentage PDK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435961Percentage CDK2-cyclinA activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435811Percentage PIM1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514805Inhibition of SRPK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514817Inhibition of TEK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514436Inhibition of MAP3K9 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435466Percentage ERK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514025Inhibition of CSNK2A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514783Inhibition of PTK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435755Percentage SmMLCK activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435981Percentage p38alpha activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435236Percentage JNK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435251Percentage MST2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514333Induction of AKT1 Thr308 phosphorylation expressed in IGF1-stimulated HEK293 cells treated 20 mins before IGF1 stimulation by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435372Percentage p38-gamma activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435604Percentage IKK-beta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435922Percentage PIM3 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435839Percentage AMPK activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514802Inhibition of SRC N1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435237Percentage JNK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514074Inhibition of INSRR at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514771Inhibition of PKCG at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514464Inhibition of NEK7 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514431Inhibition of LYN B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514789Inhibition of ROCK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514027Inhibition of DAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514076Inhibition of ITK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514800Inhibition of SGKL at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435978Percentage MST2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514432Inhibition of MAP2K1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514490Inhibition of PRKCB2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514429Inhibition of LTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513808Inhibition of BLK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290883Selectivity for Akt1 over PKCgamma2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514473Inhibition of PAK7 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514075Inhibition of IRAK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514016Inhibition of CLK3 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290885Selectivity for Akt1 over CDK22007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435964Percentage DYRK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514452Inhibition of MERTK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514077Inhibition of JAK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514457Inhibition of MST4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514023Inhibition of CSNK1G2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435872Percentage PAK4 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435986Percentage PLK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435589Percentage CHK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID1876208Binding affinity to AKT1 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
AID436081Percentage ERK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514031Inhibition of DYRK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514033Inhibition of EGFR at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435914Percentage PAK5 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513818Inhibition of CAMK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513785Induction of membrane localization of AKT1 in HEK293 cells at 2.5 uM after 15 mins by anti AKt antibody staining based fluorescence microscopy2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514011Inhibition of CDK2/cyclin A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514445Inhibition of MAPK3 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435960Percentage CaMKKalpha activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435477Percentage MNK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435634Percentage Src activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514790Inhibition of ROS1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514029Inhibition of DYRK1A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514435Inhibition of MAP3K8 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435229Percentage ERK8 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435633Percentage SGK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514437Inhibition of MAP4K2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514462Inhibition of NEK4 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435299Percentage PAK5 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514332Inhibition of wild type AKT1 expressed in HEK293 cells assessed as reduction of IGF1-induced GSK3-beta Ser9 phosphorylation treated 20 mins before IGF1 stimulation by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514454Inhibition of MET M1250T mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435548Percentage CaMKKalpha activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID266587Oral bioavailability in mouse at 10 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
ISSN: 0960-894X
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID514787Inhibition of RET Y791F mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513800Inhibition of ADRBK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435492Percentage PKD1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514463Inhibition of NEK6 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514014Inhibition of CLK1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514489Inhibition of PRKCB1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514801Inhibition of SRC at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435177Percentage PKA activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514803Inhibition of SRMS at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514021Inhibition of CSNK1E at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514062Inhibition of GRK4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435232Percentage HIPK3 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514479Inhibition of PHKG1 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514329Inhibition of myristoylated AKT2 M225G mutant expressed in HEK293T cells by in vitro immunoprecipitation kinase assay2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514476Inhibition of PDGFRalpha T674I mutant at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID290895Selectivity for Akt1 over RSK22007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID514794Inhibition of RPS6KA4 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514030Inhibition of DYRK1B at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514328Inhibition of myristoylated wild type AKT2 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435965Percentage EF2K activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514330Inhibition of myristoylated wild type AKT3 expressed in HEK293T cells by in vitro immunoprecipitation kinase assay2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513781Induction of flag-tagged wild type AKT1 Ser473 hyperphosphorylation expressed in HEK293 cells at 2.5 uM after 30 mins by immunoblotting2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514810Inhibition of STK25 at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514477Inhibition of PDGFRbeta at 1 uM in presence of 100 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435342Percentage CK1delta activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513799Inhibition of ADRBK1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514820Inhibition of ZAP70 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435612Percentage MNK1 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435303Percentage PHK activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID513797Inhibition of ABL2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID513804Inhibition of ALK at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435302Percentage PHK activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514026Inhibition of CSNK2A2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435134Percentage SRPK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514815Inhibition of TAOK2 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514491Inhibition of PRKCD at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435468Percentage ERK8 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID290872Inhibition of human Akt12007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID435259Percentage RSK2 activity remaining in the presence of 0.01uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514063Inhibition of GRK5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID435880Percentage ROCK2 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID435976Percentage MNK1 activity remaining in the presence of 0.1uM inhibitor2007The Biochemical journal, Dec-15, Volume: 408, Issue:3
ISSN: 1470-8728
The selectivity of protein kinase inhibitors: a further update.
AID514066Inhibition of GSK3A at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514448Inhibition of MAPKAPK5 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID514481Inhibition of PIM1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173ISSN: 1872-9096A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression2022The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X
AID1345789Human phosphorylase kinase catalytic subunit gamma 1 (Phosphorylase kinase (PHK) family)2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID1345374Human AKT serine/threonine kinase 1 (Akt (Protein kinase B))2005Molecular cancer therapeutics, Jun, Volume: 4, Issue:6
ISSN: 1535-7163
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
AID1345311Human CDC42 binding protein kinase beta (GEK subfamily)2009Nature chemical biology, Jul, Volume: 5, Issue:7
ISSN: 1552-4469
Inhibitor hijacking of Akt activation.
AID1345349Human AKT serine/threonine kinase 2 (Akt (Protein kinase B))2005Molecular cancer therapeutics, Jun, Volume: 4, Issue:6
ISSN: 1535-7163
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
AID1345907Human AKT serine/threonine kinase 3 (Akt (Protein kinase B))2005Molecular cancer therapeutics, Jun, Volume: 4, Issue:6
ISSN: 1535-7163
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
AID1797513Akt Kinase Assay from Article 10.1021/jm0701019: \\Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension.\\2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID1797358PKB In Vitro Enzyme Assay from Article 10.1016/j.jmb.2007.01.004: \\A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.\\2007Journal of molecular biology, Mar-30, Volume: 367, Issue:3
ISSN: 0022-2836
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
AID1797514PKA/PKC Kinase Assay from Article 10.1021/jm0701019: \\Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase b/akt inhibitors with reduced hypotension.\\2007Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13
ISSN: 0022-2623
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
AID1797359PKA In Vitro Enzyme Assay from Article 10.1016/j.jmb.2007.01.004: \\A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.\\2007Journal of molecular biology, Mar-30, Volume: 367, Issue:3
ISSN: 0022-2836
A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.
AID1797345Akt Kinase Assay from Article 10.1016/j.bmcl.2006.04.046: \\Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.\\2006Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14
ISSN: 0960-894X
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (39.53)29.6817
2010's18 (41.86)24.3611
2020's8 (18.60)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other43 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
indoleacetamideindoles;
monocarboxylic acid amide;
N-acylammonia
bacterial metabolite;
fungal metabolite;
plant metabolite
00low000000
bisindolylmaleimide iiiindoles;
maleimides
EC 2.7.11.13 (protein kinase C) inhibitor00low000000
bisindolylmaleimide ivindoles;
maleimides
00low000000
bisindolylmaleimide vindoles00low000000
chetominindoles;
organic disulfide;
organic heteropentacyclic compound
Chaetomium metabolite;
immunosuppressive agent
00low000000
dapiindolesfluorochrome00low000000
3,3'-diindolylmethaneindolesantineoplastic agent;
P450 inhibitor
00low000000
gö6983indoles;
maleimides
00low000000
ic 261indoles00low000000
indapamideindoles;
organochlorine compound;
sulfonamide
antihypertensive agent;
diuretic
00low000000
indolepropanol phosphateindoles;
monoalkyl phosphate
00low000000
linopirdineindoles00low000000
pindololindoles;
secondary amine
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
00low000000
3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-oneindoles00low000000
ro 31-8220imidothiocarbamic ester;
indoles;
maleimides
EC 2.7.11.13 (protein kinase C) inhibitor00low000000
ici 204,219carbamate ester;
indoles;
N-sulfonylcarboxamide
anti-asthmatic agent;
leukotriene antagonist
00low000000
adrenochromeindoles00low000000
5-bromoisatinindolesanticoronaviral agent00low000000
etryptamineindoles00low000000
hydroxytryptopholindoles00low000000
indole-3-carbaldehydeheteroarenecarbaldehyde;
indole alkaloid;
indoles
bacterial metabolite;
human xenobiotic metabolite;
marine metabolite;
plant metabolite
00low000000
indicanaryl sulfate;
indoles
human metabolite00low000000
indolineindoles00low000000
indoxyl acetateindoles00low000000
methoxytryptopholindoles00low000000
5-methoxyindoleindoles00low000000
iprindoleindoles00low000000
mebhydrolineindoles00low000000
molindoneindoles00low000000
oxyphenisatinindoles00low000000
5-Methoxyisatinindolesanticoronaviral agent00low000000
indalpineindoles00low000000
5-bromo-4-chloro-3-indoxyl phosphatearyl phosphate;
indoles;
organobromine compound;
organochlorine compound
chromogenic compound00low000000
geneserineindoles00low000000
ropinirole hydrochlorideindoles00low000000
tinazolineindoles00low000000
n-acetyltryptamineacetamides;
indoles
00low000000
mepindololindoles00low000000
eletriptanindoles;
N-alkylpyrrolidine;
sulfone
non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
00low000000
5-methoxyindole-3-carbaldehydeindoles00low000000
6-chloroindoleindoles00low000000
5-Chloro-1H-indole-2,3-dioneindolesanticoronaviral agent00low000000
5-iodoisatinindolesanticoronaviral agent00low000000
lyngbyatoxin aindoles00low000000
indolactam vindoles00low000000
indo-1indolesfluorochrome00low000000
ramosetron hydrochlorideindoles00low000000
ramosetronindoles00low000000
5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1h indoleindoles00low000000
echinuline2,5-diketopiperazines;
indole alkaloid;
indoles;
olefinic compound
Aspergillus metabolite;
marine metabolite;
plant metabolite
00low000000
luzindoleacetamides;
indoles
melatonin receptor antagonist00low000000
almotriptanindoles;
sulfonamide;
tertiary amine
non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
00low000000
sb 200646indoles00low000000
tilivallineindole alkaloid;
indoles;
phenols;
pyrrolobenzodiazepine
bacterial metabolite;
microtubule-stabilising agent;
toxin
00low000000
asperlicin casperlicins;
indoles;
organic heterotetracyclic compound
Aspergillus metabolite;
cholecystokinin antagonist
00low000000
sandoz-21-009indoles00low000000
pendolmycinindolesmetabolite00low000000
cyanopindololindoles00low000000
varespladibaromatic ether;
benzenes;
dicarboxylic acid monoamide;
indoles;
monocarboxylic acid;
primary carboxamide
anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor
00low000000
leukodopachromehydroxy monocarboxylic acid;
indoles
metabolite00low000000
3,3-bis(4-hydroxy-3-methylphenyl)-1H-indol-2-oneindoles00low000000
3-methyleneindolenineindolesmetabolite00low000000
sb 216763indoles;
maleimides
00low000000
enzastaurinindoles;
maleimides
00low000000
brevianamide fdipeptide;
indoles;
pyrrolopyrazine
metabolite00low000000
3-(hydroxyacetyl)indoleindoles00low000000
roxindoleindolesalpha-adrenergic antagonist;
serotonergic drug
00low000000
5-Fluoroisatinindolesanticoronaviral agent00low000000
beta-indol-3-yl-glucosideglycoside;
indoles
00low000000
2-methyl-3-(phenylmethylthio)-1H-indoleindoles00low000000
indole-3-acetonitrileindoles;
nitrile
auxin;
human xenobiotic metabolite;
plant hormone;
plant metabolite
00low000000
10H-[1]benzothiolo[3,2-b]indoleindoles00low000000
2,2,2-trifluoro-N-[2-(1H-indol-3-yl)ethyl]acetamideindoles;
secondary carboxamide;
trifluoroacetamide
00low000000
physovenineindoles00low000000
dendrobineindoles00low000000
ck-0944666benzamides;
indoles;
organofluorine compound
actin polymerisation inhibitor00low000000
methyl indole-3-carboxylateindoles;
methyl ester
metabolite00low000000
2-(1H-indol-3-ylthio)acetic acidindoles00low000000
3-(4-pyridyl)-1h-indoleindoles00low000000
1-(2,3-dihydroindol-1-yl)-2-(5-pyridin-4-yl-2-tetrazolyl)ethanoneindoles00low000000
2-(6-cyano-1-indolyl)-N-cyclohexylacetamideindoles00low000000
1-methyl-2-[(4-methyl-1-piperidinyl)methyl]-3-indolecarbonitrileindoles00low000000
4-(1-methylsulfonyl-2,3-dihydroindol-5-yl)-N-(2-oxolanylmethyl)-2-thiazolamineindoles00low000000
N-[4-(2-methyl-1-methylsulfonyl-2,3-dihydroindol-5-yl)-2-thiazolyl]-2-thiophen-2-ylacetamideindoles00low000000
1-[5-(2-amino-5-methyl-4-thiazolyl)-2,3-dihydroindol-1-yl]-1-butanoneindoles00low000000
2-(2-methyl-1H-indol-3-yl)ethanolindoles00low000000
2-(2-ethyl-1-piperidinyl)-1-(2-methyl-1H-indol-3-yl)ethanoneindoles00low000000
1-(2,6-dimethyl-1H-indol-3-yl)-2-(1-pyrrolidinyl)ethanoneindoles00low000000
1-methyl-2-[(phenylthio)methyl]-3-indolecarbonitrileindoles00low000000
1-(2,3-dihydroindol-1-yl)-2-(phenylthio)ethanoneindoles00low000000
2-(2,3-dihydroindol-1-yl)-N,N-dimethylethanamineindoles00low000000
8-(1H-indol-3-ylmethylidene)-6,10-dioxaspiro[4.5]decane-7,9-dioneindoles00low000000
N-(1-acetyl-2-chloro-3-indolyl)-2-chloroacetamideindoles00low000000
4-(5-methoxy-1,2-dimethyl-3-indolyl)-2-thiazolamineindoles00low000000
N-(1-acetyl-2,3-dihydroindol-5-yl)-4-methylbenzamideindoles00low000000
oncrasin-1arenecarbaldehyde;
indoles;
monochlorobenzenes
antineoplastic agent;
apoptosis inducer
00low000000
1-(2-methyl-1H-indol-3-yl)-2-(2-thiazolylamino)ethanoneindoles00low000000
N-(2-fluorophenyl)-2-[3-(1-oxopropyl)-1-indolyl]acetamideindoles00low000000
2-(3-acetyl-1-indolyl)-N-(2,4-dimethylphenyl)acetamideindoles00low000000
4-amino-2-[[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]thio]-5-pyrimidinecarboxylic acid ethyl esterindoles00low000000
LSM-33266indoles00low000000
1-oxo-3-(1-piperidinyl)-5,6,7,8-tetrahydropyrrolo[1,2-a]indole-2-carbonitrileindoles00low000000
[1-(2-phenoxyethyl)-3-indolyl]-(1-pyrrolidinyl)methanethioneindoles00low000000
N-[4-(1-methylsulfonyl-2,3-dihydroindol-5-yl)-2-thiazolyl]acetamideindoles00low000000
1-[2-(1H-indol-3-yl)ethyl]-5,6,7,8-tetrahydroquinolin-4-oneindoles00low000000
N,N-diethylcarbamodithioic acid [2-(2-methyl-1H-indol-3-yl)-2-oxoethyl] esterindoles00low000000
1-(3-phenoxypropyl)-3-indolecarbonitrileindoles00low000000
1-[(3,4-dichlorophenyl)methyl]indole-2,3-dioneindoles00low000000
2-[[1-[(3-fluorophenyl)methyl]-3-indolyl]sulfonyl]-N-(5-methyl-3-isoxazolyl)acetamideindoles00low000000
1-[2-(2,5-dimethyl-1H-indol-3-yl)ethyl]-3-methyl-1-(thiophen-2-ylmethyl)thioureaindoles00low000000
2-(1H-indol-3-yl)-2-oxo-N-(2-thiazolyl)acetamideindoles00low000000
N-(2-furanylmethyl)-2-[3-(1-oxo-2-phenoxyethyl)-1-indolyl]acetamideindoles00low000000
4-(1H-indol-3-yl)butanoic acid [2-(4-amino-1,3-dimethyl-2,6-dioxo-5-pyrimidinyl)-2-oxoethyl] esterindoles00low000000
2,5-dimethyl-3-furancarboxylic acid [2-(2,3-dihydroindol-1-yl)-2-oxoethyl] esterindoles00low000000
2-chloro-3-pyridinecarboxylic acid [2-(2,3-dihydroindol-1-yl)-2-oxoethyl] esterindoles00low000000
4-(1H-indol-3-yl)butanoic acid [2-(3-methoxyanilino)-2-oxoethyl] esterindoles00low000000
2-(2,3-dihydro-1H-inden-5-yloxy)-1-(2,3-dihydroindol-1-yl)ethanoneindoles00low000000
1H-indol-3-yl(pyridin-2-yl)methanolindoles00low000000
N-(1H-indol-5-yl)-2-thiophenecarboxamideindoles00low000000
4-[[1-[(3,4-dichlorophenyl)methyl]-3-indolyl]-(3-methyl-5-oxo-1,2-dihydropyrazol-4-yl)methyl]-5-methyl-1,2-dihydropyrazol-3-oneindoles00low000000
2-methyl-3-[(2-methyl-1H-indol-3-yl)-(2-pyridinyl)methyl]-1H-indoleindoles00low000000
N-[amino-[2-(1H-indol-3-yl)ethylimino]methyl]-4-chlorobenzamideindoles00low000000
3-[2-(2,4-dimethyl-3-furanyl)-2-oxoethyl]-3-hydroxy-1-(2-phenylethyl)-2-indoloneindoles00low000000
1-[2-(hydroxymethyl)-1-benzimidazolyl]-3-(1-indolyl)-2-propanolindoles00low000000
6-(2-chlorophenyl)-3-methyl-2-[4-morpholinyl(oxo)methyl]-1,5,6,7-tetrahydroindol-4-oneindoles00low000000
3-methyl-4-oxo-1,5,6,7-tetrahydroindole-2-carboxylic acid (4-methylcyclohexyl) esterindoles00low000000
5-[[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]methyl]-2-furancarboxylic acid methyl esterindoles00low000000
N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamideindoles00low000000
2-[(prop-2-enylthio)-(4,5,6,7-tetrahydro-1H-indol-2-yl)methylidene]propanedinitrileindoles00low000000
2-[[5-(dimethylsulfamoyl)-1H-indol-3-yl]methylidene]propanedioic acid diethyl esterindoles00low000000
5-methyl-1-[3-(2-methylphenoxy)propyl]indole-2,3-dioneindoles00low000000
N-[2-(1H-indol-3-yl)ethyl]-4-(phenylmethyl)-5-thieno[3,2-b]pyrrolecarboxamideindoles00low000000
1-[cyclopropyl(oxo)methyl]-N-(2-hydroxyethyl)-N-(phenylmethyl)-2,3-dihydroindole-5-sulfonamideindoles00low000000
5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamideindoles00low000000
4-(1-methyl-3-indolyl)-N-propan-2-ylbutanamideindoles00low000000
4-(2,3-dihydroindol-1-yl)-N-[3-(N-ethyl-3-methylanilino)propyl]-3-(1-imidazolyl)-4-oxobutanamideindoles00low000000
1-[[5-bromo-1-[cyclopropyl(oxo)methyl]-2,3-dihydroindol-7-yl]sulfonyl]-4-piperidinecarboxylic acid ethyl esterindoles00low000000
N-[2-(2-methyl-1-indolyl)ethyl]benzamideindoles00low000000
3-[[5-bromo-1-[cyclopropyl(oxo)methyl]-2,3-dihydroindol-7-yl]sulfonyl]-N-[(5-methyl-2-furanyl)methyl]propanamideindoles00low000000
acetic acid [2-(1-acetyl-6-indolyl)-2-oxoethyl] esterindoles00low000000
N-[2-(1-cyclohexenyl)ethyl]-1-[cyclopropyl(oxo)methyl]-2,3-dihydroindole-5-sulfonamideindoles00low000000
4-[2-[[1-[(2-methylphenyl)methyl]-3-indolyl]sulfonyl]-1-oxoethyl]-1-piperazinecarboxylic acid ethyl esterindoles00low000000
N-[4-(dimethylamino)phenyl]-2-(1-oxo-[1,2,4]triazino[4,5-a]indol-2-yl)acetamideindoles00low000000
N-(3-methoxyphenyl)-2-(1-methyl-3-indolyl)acetamideindoles00low000000
cyclobutyl-[5-[(2-ethyl-1-piperidinyl)sulfonyl]-2,3-dihydroindol-1-yl]methanoneindoles00low000000
n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea1,2-thiazoles;
indoles;
ureas
receptor modulator;
serotonergic antagonist
00low000000
n-pentanoyl-2-benzyltryptamineindoles00low000000
2-[[1-(phenylmethyl)-3-indolyl]thio]-N-(2-thiazolyl)acetamideindoles00low000000
[1-[2-(2-methylphenoxy)ethyl]-3-indolyl]-(4-methyl-1-piperazinyl)methanethioneindoles00low000000
1-(Chloroacetyl)-3-(1H-indol-3-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-4-olindolesanticoronaviral agent00low000000
N-[(1,2-dimethyl-5-indolyl)methyl]-2-methyl-3-nitrobenzamideindoles00low000000
N-(2-furanylmethyl)-2-[[5-[(2-methyl-1H-indol-3-yl)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamideindoles00low000000
l 663536aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes
antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
00low000000
2-[(1-methyl-3-indolyl)thio]-N-(2-thiazolyl)acetamideindoles00low000000
Nb-Palmitoyltryptamineindoles00low000000
rs 17053indoles00low000000
N-[2-(2-chlorophenoxy)ethyl]-2-(1H-indol-3-yl)-2-oxoacetamideindoles00low000000
1-(1H-indol-3-yl)-2-[(6-methyl-2-nitro-3-pyridinyl)oxy]ethanoneindoles00low000000
1-[2-(5-chloro-2-methyl-1H-indol-3-yl)ethyl]-3-ethyl-1-(2-furanylmethyl)thioureaindoles00low000000
5-bromo-N-[(1,2-dimethyl-5-indolyl)methyl]-2-furancarboxamideindoles00low000000
1-[(1,2-dimethyl-5-indolyl)methyl]-3-(phenylmethyl)thioureaindoles00low000000
4-chloro-N-[2-(1H-indol-3-yl)-1-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)ethyl]benzamideindoles00low000000
1-cyclohexyl-3-[(1,2-dimethyl-5-indolyl)methyl]ureaindoles00low000000
5-bromo-N-[2-(2-methyl-1-indolyl)ethyl]-2-furancarboxamideindoles00low000000
le 300indoles00low000000
4-[(1,2-dimethyl-5-indolyl)methylamino]-4-oxobutanoic acidindoles00low000000
5-Nitroisatinindolesanticoronaviral agent00low000000
1-[2-(2,4-dichlorophenyl)-2-(1H-indol-3-yl)ethyl]-3-[3-(dimethylamino)propyl]thioureaindoles00low000000
N-[2-[4-(dimethylamino)phenyl]-2-(1H-indol-3-yl)ethyl]benzamideindoles00low000000
2,6-difluoro-N-[2-[3-[(2-fluorophenyl)methylthio]-1-indolyl]ethyl]benzamideindoles00low000000
ro 60-0175indoles;
organochlorine compound;
organofluorine compound;
primary amino compound
00low000000
N-[(1,2-dimethyl-5-indolyl)methyl]-2-(4-nitrophenyl)acetamideindoles00low000000
2-[[4-amino-5-(3,4-dimethoxyphenyl)-1,2,4-triazol-3-yl]thio]-1-(1H-indol-3-yl)-2-phenylethanoneindoles00low000000
1-acetyl-N-[3-(N-ethyl-3-methylanilino)propyl]-2,3-dihydroindole-5-sulfonamideindoles00low000000
3-[3-[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl]-1H-benzimidazol-2-oneindoles00low000000
koumineindoles00low000000
AG-370indoles00low000000
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic aciddihydroxy monocarboxylic acid;
indoles;
organofluorine compound
00low000000
apaziquoneindoles00low000000
amaranthin betacyanindisaccharide derivative;
indoles;
olefinic compound;
tetrahydropyridine
biological pigment;
plant metabolite
00low000000
(5-ethyl-8-methyl-[1,2,4]triazino[5,6-b]indol-3-yl)hydrazineindoles00low000000
chaetoglobosin Acytochalasan alkaloid;
epoxide;
indoles;
macrocycle;
secondary alpha-hydroxy ketone
Chaetomium metabolite00low000000
LSM-18452indoles00low000000
(2R,4R)-4-(1-acetyl-3-indolyl)-2-[[4-(hydroxymethyl)phenyl]methoxy]-N-(phenylmethyl)-3,4-dihydro-2H-pyran-6-carboxamideindoles00low000000
vilazodone1-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile
antidepressant;
serotonergic agonist;
serotonin uptake inhibitor
00low000000
cyclo(glycyltryptophyl)indolesmetabolite00low000000
2-[(1R,3S)-3-(7-bromo-2-methyl-1H-indol-3-yl)-2,2-dimethylcyclopropyl]acetonitrileindoles00low000000
(11S,14S)-Cyclo-(L-Trp-L-Phe)indolesAspergillus metabolite00low000000
LSM-3706indoles00low000000
LSM-3511indoles00low000000
LSM-2818indoles00low000000
tryprostatin bdipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine
00low000000
l 779976benzimidazoles;
indoles;
piperidinecarboxamide;
primary amino compound;
secondary carboxamide
neuroprotective agent;
somatostatin receptor agonist
00low000000
tmc-95aindoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
fungal metabolite;
proteasome inhibitor
00low000000
nematophinindoles00low000000
molindone hydrochlorideindoles00low000000
varespladib methylaromatic ether;
benzenes;
indoles;
methyl ester;
primary carboxamide
anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor;
prodrug
00low000000
am 694aromatic ketone;
indoles;
organofluorine compound;
organoiodine compound;
synthetic cannabinoid
cannabinoid receptor agonist00low000000
tryprostatin aaromatic ether;
dipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine
breast cancer resistance protein inhibitor00low000000
way-362450indoles00low000000
fumiquinazoline ffumiquinazoline;
indoles;
pyrazinoquinazoline
00low000000
5-chloro-2-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indoleindoles00low000000
noradrenochromeindoles00low000000
sotrastaurinindoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines
anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
00low000000
tmc-95bindoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol
antimicrobial agent;
antineoplastic agent;
fungal metabolite;
proteasome inhibitor
00low000000
chromopyrrolic acidindoles;
pyrroledicarboxylic acid
bacterial metabolite00low000000
arq 197indoles00low000000
quisinostatindoles00low000000
pf-562,271indoles00low000000
Dihydro-beta-erythroidine hydrobromideindoles00low000000
N-[5-(2,3-dihydroindol-1-ylsulfonyl)-1,3,4-thiadiazol-2-yl]-3-methylbutanamideindoles00low000000
complestatincyclic ether;
heterodetic cyclic peptide;
indoles;
organic heterobicyclic compound;
organochlorine compound;
peptide antibiotic;
polyphenol
anti-HIV-1 agent;
antimicrobial agent;
HIV-1 integrase inhibitor;
metabolite
00low000000
neuroprotectin acyclic ether;
heterodetic cyclic peptide;
indoles;
organochlorine compound;
polyphenol
HIV-1 integrase inhibitor;
metabolite
00low000000
2-[3-[[2-oxo-2-(1-pyrrolidinyl)ethyl]thio]-1-indolyl]-N,N-di(propan-2-yl)acetamideindoles00low000000
1-[3-[(2R,4R)-2-[[4-(hydroxymethyl)phenyl]methoxy]-6-[oxo-[4-(phenylmethyl)-1-piperazinyl]methyl]-3,4-dihydro-2H-pyran-4-yl]-1-indolyl]ethanoneindoles00low000000
3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-oneindoles00low000000
2-[1-[2-(diethylamino)-2-oxoethyl]-3-indolyl]-N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoacetamideindoles00low000000
1-[(2-oxo-1,3-dihydroindol-5-yl)sulfonyl]-4-piperidinecarboxylic acid ethyl esterindoles00low000000
N-(4-propan-2-ylphenyl)-1-[(1,3,3-trimethyl-2-oxo-5-indolyl)sulfonyl]-4-piperidinecarboxamideindoles00low000000
N-[4-[1-(1-oxopropyl)-2,3-dihydroindol-5-yl]-2-thiazolyl]-2-furancarboxamideindoles00low000000
cink4indoles00low000000
chondramide cchondramide;
indoles;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
2-[[1-[(3-chlorophenyl)methyl]-3-indolyl]sulfonyl]-N-(5-methyl-3-isoxazolyl)acetamideindoles00low000000
2-[[1-[(3-bromophenyl)methyl]-3-indolyl]sulfonyl]-N-(5-methyl-3-isoxazolyl)acetamideindoles00low000000
wasalexin aindoles00low000000
chondramide achondramide;
indoles;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholineindoles00low000000
gsk2656157biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
00low000000
AZD3463aminopiperidine;
aminopyrimidine;
indoles;
monomethoxybenzene;
organochlorine compound;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
osimertinibacrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
00low000000
acarbosechondramide;
indoles;
organochlorine compound;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
chondramide dchondramide;
indoles;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
THZ531aminopyrimidine;
enamide;
indoles;
N-acylpiperidine;
organochlorine compound;
secondary amino compound;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
lugduninhomodetic cyclic peptide;
indoles;
macrocycle;
peptide antibiotic;
thiazolidines
human metabolite;
rat metabolite
00low000000
tegaserodcarboxamidine;
guanidines;
hydrazines;
indoles
gastrointestinal drug;
serotonergic agonist
00low000000
brassilexinindoles00low000000
indolmycin1,3-oxazoles;
indoles;
secondary amino compound
antibacterial agent;
antimicrobial agent;
bacterial metabolite;
EC 6.1.1.2 (tryptophan--tRNA ligase) inhibitor
00low000000
N'-(1h-indol-3-ylmethylene)benzohydrazideindoles00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
bisindolylmaleimide ivindoles;
maleimides
202220222.0low000001
go 6976indolocarbazole;
organic heterohexacyclic compound
EC 2.7.11.13 (protein kinase C) inhibitor2007200717.0low000100
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamideisoquinolines;
sulfonamide
2007200717.0low000100
fasudilisoquinolines;
N-sulfonyldiazepane
antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
2007200717.0low000100
harmalineharmala alkaloidoneirogen2007200717.0low000100
harmalolharmala alkaloidalgal metabolite;
EC 1.4.3.4 (monoamine oxidase) inhibitor
2007200717.0low000100
ic 261indoles2007200717.0medium000100
nsc 664704indolobenzazepine;
lactam;
organobromine compound
cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
2007200717.0low000100
leflunomide(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide
antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
202220222.0low000001
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-onechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
200720229.5low000101
olomoucine2,6-diaminopurines;
ethanolamines
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor202220222.0low000001
1-NA-PP1pyrazolopyrimidinetyrosine kinase inhibitor2007200717.0low000100
ag 1879aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine
beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
2007200717.0low000100
ro 31-8220imidothiocarbamic ester;
indoles;
maleimides
EC 2.7.11.13 (protein kinase C) inhibitor2007200717.0low000100
sb 202190imidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
2007200717.0low000100
tyrphostin a9alkylbenzenegeroprotector202220222.0low000001
zm 336372benzamides2007200717.0low000100
pyrazolanthroneanthrapyrazole;
aromatic ketone;
cyclic ketone
antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
2007200717.0low000100
imatinib mesylatemethanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
202220222.0low000001
gefitinibaromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
202220222.0low000001
lestaurtinibindolocarbazole202220222.0low000001
cki 7isoquinolines;
organochlorine compound;
primary amino compound;
sulfonamide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor2007200717.0low000100
ruboxistaurin2007200717.0low000100
canertinibmonochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
202220222.0low000001
birb 796aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
2007200717.0low000100
cyc 2022,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
200720229.5low000101
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
200720229.5low000101
sb 216763indoles;
maleimides
2007200717.0low000100
erlotinibaromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound
antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
202220222.0low000001
sorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide
angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
200720229.5low000101
wortmanninacetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound
anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
2007200717.0low000100
pd 166326202220222.0low000001
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea2007200717.0low000100
y 27632aromatic amide2007200717.0low000100
h 1152isoquinolines;
N-sulfonyldiazepane
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor2007200717.0medium000100
h 89N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide2007200916.0low000200
purvalanol apurvalanol200720229.5low000101
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
202220222.0low000001
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenolsubstituted aniline202220222.0low000001
Src Inhibitor-1aromatic ether;
polyether;
quinazolines;
secondary amino compound
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor2007200717.0low000100
sc 514ring assembly;
thiophenes
2007200717.0low000100
u 0126aryl sulfide;
dinitrile;
enamine;
substituted aniline
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
200720229.5low000101
dasatinib1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
202220222.0low000001
7-epi-hydroxystaurosporine2007200717.0medium000100
sb 415286C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline
antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
2007200717.0low000100
alsterpaulloneC-nitro compound;
caprolactams;
organic heterotetracyclic compound
anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
200720229.5low000101
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-yleminepyrazolopyrimidinetyrosine kinase inhibitor2007200717.0low000100
harmineharmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
2007200717.0low000100
genistein7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
202220222.0low000001
harmanharmala alkaloid;
indole alkaloid fundamental parent;
indole alkaloid
anti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
2007200717.0low000100
rottlerinaromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone
anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
200720229.5low000101
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
2007200717.0low000100
alvocidibdihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
202220222.0low000001
3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamidepyrimidines202220222.0low000001
su 66562007200717.0low000100
bosutinibaminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
202220222.0low000001
orantinib2007200717.0low000100
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
202220222.0low000001
palbociclibaminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
202220222.0low000001
vx680N-arylpiperazine2007200717.0low000100
viroxime202220222.0low000001
d 4476imidazoles2007200717.0low000100
everolimuscyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol
anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
202220222.0low000001
pd 184352aminobenzoic acid200720229.5low000101
bibx 1382bssubstituted aniline202220222.0low000001
vacuolin-1202220222.0low000001
bms345541quinoxaline derivative2007200717.0low000100
pd 0325901difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound
antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
200720229.5low000101
midostaurinbenzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
202220222.0low000001
pi103aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
2007200717.0low000100
tofacitinibN-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound
antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
202220222.0low000001
ps1145beta-carbolines2007200717.0low000100
chir 99021aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound
EC 2.7.11.26 (tau-protein kinase) inhibitor2007200717.0low000100
osu 03012antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
202220222.0low000001
bx795ureas2007202211.3low000201
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
202220222.0low000001
apilimod202220222.0low000001
pik 75202220222.0low000001
saracatinibaromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
202220222.0low000001
sl01012007200717.0low000100
regorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide
antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
202220222.0low000001
at 7867monochlorobenzenes;
piperidines;
pyrazoles
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
2009200915.0low000100
bi 2536202220222.0low000001
dorsomorphinaromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines
bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
2007200717.0low000100
crizotinib3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
202220222.0low000001
cgp 57380pyrazolopyrimidine2007200717.0low000100
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
202220222.0low000001
pha 767491pyrrolopyridine202220222.0low000001
dactolisibimidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
202220222.0low000001
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amideorganochlorine compound202220222.0low000001
azd8330pyridinecarboxamide202220222.0low000001
fedratinibsulfonamide202220222.0low000001
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene202220222.0low000001
pci 32765acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
202220222.0low000001
mk 2206organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor202220222.0low000001
bi d18702007200717.0medium000100
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideaminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound
anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
202220222.0low000001
incb-018424nitrile;
pyrazoles;
pyrrolopyrimidine
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
202220222.0low000001
fit-039202220222.0low000001
azd2014202220222.0low000001
bay 869766202220222.0low000001
baricitinibazetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide
anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
202220222.0low000001
4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide202220222.0low000001
ly2784544pyridazines202220222.0low000001
sb 1518202220222.0low000001
dinaciclibpyrazolopyrimidine202220222.0low000001
gilteritinibaromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
202220222.0low000001
glpg0634202220222.0low000001
delgocitinibazaspiro compound;
N-acylazetidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound;
tertiary carboxamide
anti-inflammatory drug;
antipsoriatic;
antiseborrheic;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
202220222.0low000001
incb039110202220222.0low000001
vx-970sulfonamide202220222.0low000001
ldc4297aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
202220222.0medium000001
at 9283202220222.0low000001
akt-i-1,2 compound2007200717.0low000100
ag-879202220222.0low000001
hesperadin202220222.0low000001
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
phosphoserinenon-proteinogenic alpha-amino acid;
O-phosphoamino acid;
serine derivative
human metabolite2008200816.0low000100
pyridineazaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines
environmental contaminant;
NMR chemical shift reference compound
2005200519.0low000100
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-onechromones;
morpholines;
organochlorine compound
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
2007201910.3low000120
serineL-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine
algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2007200717.0low000100
quinoxalinesmancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
2009200915.0low000100
indazolesindazole2005202112.0medium00014101
paclitaxeltaxane diterpenoid;
tetracyclic diterpenoid
antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
2005200519.0low000100
etoposidebeta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound
antineoplastic agent;
DNA synthesis inhibitor
2008200816.0low000100
phosphothreonineL-threonine derivative;
non-proteinogenic L-alpha-amino acid;
O-phosphoamino acid
Escherichia coli metabolite2008200816.0low000100
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
2010201610.2low000130
alpha-synuclein202120213.0low000001
4-(2-phenyl-5,7-bis(trifluoromethyl)pyrazolo(1,5-a)pyrimidin-3-yl)phenolpyrazoles;
ring assembly
201820186.0low000010
mk 2206organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor2014201410.0low000010
pf-4708671201620168.0low000010
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone2014201410.0low000010
akt-i-1,2 compound2009200915.0low000100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2019 Novel Coronavirus Disease0202220222.0low000001
Adenosis of Breast02010201014.0low000100
Age-Related Memory Disorders0201520159.0low000010
Alcohol Drinking0201820186.0low000010
Angelman Syndrome0201620168.0low000010
Anoxemia02007200717.0low000100
Astrocytoma, Grade IV02009200915.0low000100
ATLL02008200816.0low000100
B-Cell Chronic Lymphocytic Leukemia02009201014.5low000200
Benign Neoplasms02005200618.5low000200
Blood Pressure, Low02007200717.0low000100
Breast Cancer02010201710.5low000110
Breast Neoplasms02010201710.5low000110
Cancer of Pancreas02014201410.0low000010
Cancer of Prostate02010201014.0low000100
Congenital Zika Syndrome0202020204.0low000010
Disease Exacerbation02005200519.0low000100
Disease Models, Animal0202020204.0low000010
Fibrocystic Breast Disease02010201014.0low000100
Glioblastoma02009200915.0low000100
Happy Puppet Syndrome0201620168.0low000010
Hyperglycemia02010201014.0low000100
Hyperglycemia, Postprandial02010201014.0low000100
Hypotension02007200717.0low000100
Hypoxia02007200717.0low000100
Idiopathic Parkinson Disease0202120213.0low000001
Inflammation02010201014.0low000100
Innate Inflammatory Response02010201014.0low000100
Leukemia-Lymphoma, Adult T-Cell02008200816.0low000100
Leukemia, Lymphocytic, Chronic, B-Cell02009201014.5low000200
Memory Disorders0201520159.0low000010
Metastase02010201014.0low000100
Neoplasm Metastasis02010201014.0low000100
Neoplasms02005200618.5low000200
Pancreatic Neoplasms02014201410.0low000010
Parkinson Disease0202120213.0low000001
Prostatic Neoplasms02010201014.0low000100
Sensitivity and Specificity02005200519.0low000100
Viral Diseases0202220222.0low000001
Virus Diseases0202220222.0low000001
Zika Virus Infection0202020204.0low000010

Bioavailability (2)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5
2019
Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Journal of medicinal chemistry, , Jun-28, Volume: 50, Issue:13
2007

Dosage (2)

ArticleYear
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cancer biology & therapy, , Apr-01, Volume: 9, Issue:7
2010
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Molecular cancer therapeutics, , Volume: 4, Issue:6
2005